PDCD1 and melanoma: To this end, we performed subclass mapping in TCGA cohort and revealed that the nCIMP showed high transcriptional similarity with a subgroup of melanoma patients who responded to anti-PD1 blockade (adjusted P < 0.05; Figure 3C), which indicated that patients in the nCIMP subgroup can profit more from anti-PD-1 treatment.